Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixabepilone + capecitabine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ixabepilone + capecitabine is a combination chemotherapy regimen used for the treatment of metastatic or locally advanced breast cancer that is resistant to anthracyclines and taxanes, or in cases where further anthracycline therapy is contraindicated. Ixabepilone is an epothilone B analog and functions as a microtubule stabilizer by binding directly to β-tubulin subunits, suppressing their dynamic instability, blocking mitosis, and inducing cell death. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which inhibits DNA synthesis by interfering with thymidylate synthase. The combination exploits different mechanisms to overcome resistance seen with other chemotherapies. Ixabepilone was developed from natural products isolated from Sorangium cellulosum and has demonstrated efficacy in taxane-resistant cancers due to its distinct binding mode and lack of susceptibility to P-glycoprotein-mediated drug efflux[1][2][4][5][6].
- Brand names
- IxempraXeloda
- Other names
- epothilone B analog (for ixabepilone)
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on ixabepilone + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixabepilone + capecitabine.